Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris



Status:Completed
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 65
Updated:1/17/2019
Start Date:March 19, 2014
End Date:March 1, 2018

Use our guide to learn which trials are right for you!

Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)

The purpose of this study is to determine if the use of ustekinumab, followed by abatacept,
will prevent relapse in people with moderate to severe plaque psoriasis.

Psoriasis is a chronic immune disease of the skin and joints that affects about 2% of the
population. The most common form of psoriasis is plaque psoriasis, also called psoriasis
vulgaris. A variety of drugs, including biologics, are available for treatment of moderate to
severe psoriasis. When biologic agents are stopped, psoriasis can return (relapse) and often
requires the biologic to be restarted and continued. No treatment program has been identified
to prevent relapse of psoriasis.

The study design has a lead-in period of weight-based ustekinumab treatment, with all
participants receiving either 45 mg ustekinumab (<= 100 kg) or 90 mg ustekinumab (> 100 kg)
administered subcutaneously at weeks 0 and 4. At week 12, participants will be assessed for a
Psoriasis Area and Severity Index (PASI) 75 response to ustekinumab. Participants who do not
achieve a PASI 75 score will be discontinued from the investigation and permitted to seek
standard therapy.

Inclusion Criteria:

- A diagnosis of plaque psoriasis for at least 6 months

- Baseline Psoriasis Area and Severity Index (PASI) score >= 12

- >=10% body surface area psoriasis involvement

- Willingness to forgo other available psoriasis therapies, live vaccines, and pregnancy
during the trial

- Ability and willingness to provide informed consent and comply with study requirements

Exclusion Criteria:

- Non-plaque forms of psoriasis

- Grade 2 or 3 moderate to severe psoriatic arthritis not adequately managed with
non-steroidal anti-inflammatory drugs (NSAIDs)

- Myocardial infarction, unstable angina, cerebrovascular accident, or other significant
cardiovascular event within the previous one year

- Chronic obstructive pulmonary disease (COPD)

- Comorbid condition that requires regular systemic corticosteroid treatment

- History of malignancy, except treated basal cell skin carcinoma

- Treated basal cell skin carcinoma within the previous 5 years

- Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal,
pulmonary, cardiac, or neurological disease, or any other medical condition that, in
the investigator's opinion, places the participant at risk by participating in this
study

- History of recent or ongoing uncontrolled bacterial, viral, fungal, or other
opportunistic infections

- Evidence of infection with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human
Immunodeficiency Virus (HIV)

- Positive QuantiFERON-TB Gold test. Purified Protein Derivative (PPD) tuberculin test
may be substituted for QuantiFERON-TB Gold test.

- Severe reaction or anaphylaxis to any human monoclonal antibody

- Any previous treatment with agents targeting Interleukin (IL)-12 or IL-23, including
ustekinumab

- Any previous treatment with abatacept

- Treatment with biologic agents within previous 3 months, including adalimumab,
etanercept, and infliximab

- Treatment with immunosuppressive medications, including methotrexate, cyclosporine,
oral retinoids, prednisone, or phototherapy within previous 4 weeks

- Topical psoriasis treatment within previous 2 weeks, including topical
corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, salicylic
acid, and coal tar

- Investigational study medication within previous 6 months

- Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT],
or alkaline phosphatase) results that are >/= 2x the upper limit of normal (ULN).

- Serum creatinine >= 2x the ULN.

- Any of the following hematologic abnormalities, confirmed by repeat test at least 1
week apart:

1. White blood count <3,000/μL or >14,000/μL;

2. Lymphocyte count <1,000/μL;

3. Neutrophil count <1,500/μL;

4. Platelet count <150,000 /μL; or

5. Hemoglobin <10 g/dL.

- Females who are pregnant, lactating, planning on pregnancy during the study period, or
unwilling to use FDA-approved method of birth control

- Receipt of a live vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated
intranasal influenza vaccine, and smallpox) in the 6 weeks before enrollment

- BCG (Bacillus Calmette-Guérin) vaccine one year prior to enrollment
We found this trial at
9
sites
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Gerald Krueger, MD
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Y. Helfrich, MD
Phone: 734-936-4075
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Calgary, Alberta
?
mi
from
Calgary,
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Ann Laumann, MD
Phone: 312-695-4625
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44106
Principal Investigator: Neil Korman, M.D., Ph.D.
Phone: 216-983-0879
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Los Angeles, California 90045
Principal Investigator: Howard Sofen, MD
Phone: 310-337-7171
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Erin Boh, MD, PhD
Phone: 504-988-5135
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
1230 York Ave
New York, New York 10065
(212) 327-8000
Principal Investigator: James Krueger, MD
Rockefeller University The Rockefeller University is a world-renowned center for research and graduate education in...
?
mi
from
New York, NY
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
Principal Investigator: Steven Feldman, M.D., Ph.D.
Phone: 336-716-8991
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials